Evidence map›Paper›PMID 41978415›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2026

[Refractory systemic lupus erythematosus-associated thrombocytopenia treated with avatrombopag: A case report].

Xiaofei Tang, Qiuling Ding, Yang Zhang, Yumei Wang, Meiyi Tian, Zhuo Sun, Rongrong Wang, Yan Chen, Jian Liu

Abstract readCase ReportsEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaofei TangDepartment of Rheumatology and Immunology, Aerospace Center Hospital, Beijing 100049, China.
Qiuling DingDepartment of Rheumatology and Immunology, Aerospace Center Hospital, Beijing 100049, China.
Yang ZhangDepartment of Rheumatology and Immunology, Aerospace Center Hospital, Beijing 100049, China.
Yumei WangDepartment of Rheumatology and Immunology, Aerospace Center Hospital, Beijing 100049, China.
Meiyi TianDepartment of Rheumatology and Immunology, Aerospace Center Hospital, Beijing 100049, China.
Zhuo SunDepartment of Rheumatology and Immunology, Aerospace Center Hospital, Beijing 100049, China.
Rongrong WangDepartment of Rheumatology and Immunology, Aerospace Center Hospital, Beijing 100049, China.
Yan ChenDepartment of Rheumatology and Immunology, Aerospace Center Hospital, Beijing 100049, China.
Jian LiuDepartment of Rheumatology and Immunology, Aerospace Center Hospital, Beijing 100049, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombocytopenia is one of the most common hematological complications of systemic lupus erythematosus (SLE). In severe cases, it can lead to life-threatening complications such as intracranial hemorrhage, significantly affecting the prognosis of patients. Clinically, after treatment with standard-dose glucocorticoids combined with immunosuppressants (

Indexed as

BenzoatesHydrazinesLupus Erythematosus, SystemicPyrazolesThrombocytopeniaAdultFemaleHumansPregnancyReceptors, ThrombopoietinBenzoateseltrombopagHydrazinesPyrazolesReceptors, ThrombopoietinAvatrombopagSystemic lupus erythematosusThrombocytopeniaThrombopoietin receptor agonist

Identifiers

PMID41978415
PMCPMC13077340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.